FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations

Also covered by: BioPharma DiveBioSpace

The feed reports that FDA launched a rare disease framework initiative with a white paper and public engagement process. It describes plans for tailored evidence standards, more patient input and clearer regulatory expectations for developers working with small patient populations.